Skip to main content
Journals

The Invisible Scar: Energy-Based Facial Tightening Through the Lens of the Deep-Layer Facelift Surgeon

Aesthetic Surgery Journal
Aesthetic Surgery Journal

Authors: Tara M Chadab, MD, MS , Aaron L Wiegmann, MD, MS , Rod J Rohrich, MD
Abstract: Energy-based devices are widely used for facial rejuvenation; as a result, an increasing proportion of patients presenting for facelift or necklift surgery have a history of prior treatment with ultrasound- or radiofrequency-based technologies. While the efficacy and safety of these devices are well established, their cumulative effects on facial soft tissues critical to deep-layer facelift surgery remain under-recognized. This article examines three commonly used energy-based facial tightening modalities—microfocused ultrasound, high-frequency parallel beam ultrasound, and fractional radiofrequency microneedling—from the perspective of the facelift surgeon. Device-specific mechanisms of action and tissue-level effects are reviewed, followed by discussion of their potential operative implications and the senior author's experience-informed strategies for managing these patients. Recognition of these effects is essential for patient counseling, operative planning, and preservation of long-lasting surgical outcomes.

JOURNAL ARTICLE

Related Articles

Recurrent herpes labialis (RHL) is a common condition characterized by episodic viral reactivation triggered by local or systemic factors. Hyaluronic acid (HA) lip augmentation is widely performed for aesthetic purposes, yet its potential association with changes in herpes labialis recurrence has not been systematically evaluated. The aim of this study was to investigate whether repeated lip augmentation with HA filler is associated with changes in the incidence of RHL episodes over time.
Resident-run clinics (RRCs) have become an important component of plastic surgery training. This study evaluates outcomes from a longitudinal RRC focused on neuromodulator and soft tissue filler injections over a 5-year period. The aim of this study was to assess clinical outcomes, patient retention, resident experience by postgraduate year (PGY) level, and the safety of RRCs as a training model.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.